SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons sharp move is drawing attention after Morgan Stanley named it a top pick, citing accelerating AWS growth and AI opportunities; traders are also pointing to Amazons Trainium software announcement as a potential boost to cloud-chip adoption. The reaction is broadly bullish, though some remain cautious about heavy AI capital spending and whether the gains will hold.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares surged after bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, supporting a planned FDA resubmission. Traders are debating whether the move can continue, with some citing short-squeeze potential and others warning of profit-taking, safety concerns around dizziness, and the fact that FDA approval is still pending.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Reports of Lundbecks interest in acquiring Xeris have fueled heavy-volume trading and takeover speculation, though the company has said it is not for sale and no deal is confirmed. Traders are split between expecting further buyer interest and viewing the chatter as unsubstantiated, while some point to Recorlev growth and XP-8121s pipeline potential as standalone reasons for optimism.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

The FDA-cleared expansion of Alpha Taus REGAIN trial in recurrent glioblastoma is a key focus, alongside planned trial data at SNO 2026. Traders are optimistic about early local-control results, while some note that they come from a small initial cohort; the completed enrollment of the pancreatic IMPACT study is another pipeline catalyst discussed.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Anticipation of Vicors Q3 earnings is driving discussion after the company raised its sequential growth outlook twice, with traders pointing to higher royalties from its Vertical Power Delivery licensing. Bulls expect the stronger outlook to show up in results, while others are wary of the sharp pullback and volatility despite the guidance increases.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO decline dominates discussion, with traders pointing to insider selling and upcoming share unlocks alongside concerns about valuation, scaling and reliance on OpenAI amid weakness across AI stocks. Some see the selloff as an oversold buying opportunity and are averaging in, while others expect further downside.

The Mosaic Co. engages in the production and marketing of concentrated phosphate and potash crop nutrients. It operates through the following segments: Phosphates, Potash, and Mosaic Fertilizantes. The Phosphates segment is involved in the ownership and operation of mines and production facilities which produce concentrated phosphate crop nutrients and phosphate-based animal feed ingredients, and processing plants which produce concentrated phosphate crop nutrients. The Potash segment includes mining, processing, and selling potash. The Mosaic Fertilizantes segment focuses on mines, chemical plants, crop nutrient blending and bagging facilities, port terminals, and warehouses. The company was founded on March 25, 2004 and is headquartered in Tampa, FL.

Mosaic Company

Mosaic is under pressure as traders focus on high sulfur costs, phosphate production curtailments, and withdrawn 2026 production guidance following weak results; the Iran-related supply disruption has raised input-cost concerns even as fertilizer prices climb. The community is split between viewing the selloff as a value opportunity amid tight fertilizer supply and worrying that squeezed margins and weaker affordability will prolong the decline.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

RGCs sharp move higher is drawing momentum-trading interest, with traders speculating about a repeat meme-stock or short-squeeze run based on its past spikes and reportedly tight share float. Others warn the move may be a pump-and-dump, citing the companys weak fundamentals and the stocks extreme volatility.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ rebounded as technology and AI stocks recovered from a sharp selloff, with traders debating whether the move marks a durable recovery or a low-volume bull trap. Upcoming megacap earnings and AI spending plans are a key focus for the tech-heavy index.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBios FDA expansion of ANKTIVA for papillary-only BCG-unresponsive bladder cancer, alongside updated long-term trial data, is driving attention. Traders are debating the sharp selloff despite the positive developments, variously attributing it to sell-the-news trading, options activity and broader biotech weakness, while others allege short manipulation; revenue growth and commercial uptake remain key concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


iq88date

iq88